Biblio

Found 6 results
Filters: Author is Bochenkova, E.  [Clear All Filters]
2025
Invernizzi A., Nai F., Bedi R.K, Vargas-Rosales P.A, Li Y., Bochenkova E., Herok M., Zálešák F., Caflisch A..  2025.  Discovery of YTHDF2 Ligands by Fragment-Based Design. ChemRxiv. X(X)
2024
Tarullo M., G. Rodriguez F, Iaiza A., Venezia S., Macone A., Incocciati A., Masciarelli S., Marchioni M., Giorgis M., Lolli M. et al..  2024.  Off-target inhibition of human dihydroorotate dehydrogenase (hDHODH) highlights challenges in the development of fat mass and obesity-associated protein (FTO) inhibitors. ACS Pharmacology & Translational Science. 7(12):4096-4111.
Errani F., Invernizzi A., Herok M., Bochenkova E., Stamm F., Corbeski I., Romanucci V., Di Fabio G., Zálešák F., Caflisch A..  2024.  Proteolysis targeting chimera degraders of the METTL3–14 m6A-RNA methyltransferase. Journal of the American Chemical Society Au. 4(2):713-729.
Zálešák F., Nai F., Herok M., Bochenkova E., Bedi R.K, Li Y., Errani F., Caflisch A..  2024.  Structure-based design of a potent and selective YTHDC1 ligand. Journal of Medicinal Chemistry. 67(11):9516-9535.
2021
Dolbois A., Bedi R.K, Bochenkova E., Müller A., Moroz-Omori E.V, Huang D., Caflisch A..  2021.  1,4,9-Triazaspiro[5.5]undecan-2-one derivatives as potent and selective METTL3 inhibitors. Journal of Medicinal Chemistry. 64(17):12738-12760.
Moroz-Omori E.V, Huang D., Bedi R.K, Cheriyamkunnel S.J, Bochenkova E., Dolbois A., Rzeczkowski M.D, Li Y., Wiedmer L., Caflisch A..  2021.  METTL3 inhibitors for epitranscriptomic modulation of cellular processes. ChemMedChem. 16(19):3035-3043.